✦ LIBER ✦

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

✍ Scribed by Christopher Wood; Pramod Srivastava; Ronald Bukowski; Louis Lacombe; Andrei I Gorelov; Sergei Gorelov; Peter Mulders; Henryk Zielinski; Axel Hoos; Florentina Teofilovici; Leah Isakov; Robert Flanigan; Robert Figlin; Renu Gupta; Bernard Escudier

Book ID: 117302933
Publisher: The Lancet
Year: 2008
Tongue: English
Weight: 312 KB
Volume: 372
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(08)60697-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A MULTICENTRE, RANDOMISED, PHASE 3 TRIAL

A MULTICENTRE, RANDOMISED, PHASE 3 TRIAL OF A NOVEL, AUTOLOGOUS, THERAPEUTIC VACCINE (VITESPEN) VS. OBSERVATION AS ADJUVANT THERAPY IN PATIENTS AT HIGH RISK OF RECURRENCE AFTER NEPHRECTOMY FOR RENAL CELL CARCINOMA

✍ P. Mulders; C.G. Wood; S. Gorelov; K. Krajka; S. Mikhailov; A. Gorelov; S.D. Fos 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 73 KB

MP-19.13: A multicenter, randomized, pha

MP-19.13: A multicenter, randomized, phase III trial of a novel autologous therapeutic vaccine (vitespen) vs. observation as adjuvant therapy in patients at high risk of recurrence after nephrectomy for renal cell carcinoma

✍ C. Wood; B. Escudier; L. Lacombe; A. Hoos; R. Gupta; R. Flanigan; R. Figlin; P. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 68 KB

POD-6.02: A Multicenter, Randomized, Pha

POD-6.02: A Multicenter, Randomized, Phase III Trial of a Novel, Autologous, Therapeutic Vaccine (Vitespen) vs. Observation as Adjuvant Therapy in Patients at High Risk of Recurrence After Nephrectomy for Renal Cell Carcinoma

✍ S. Tanguay; C. Wood; R. Bukowski; P. Champagne; P. Srivastava; B. Escudier; L. L 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 57 KB